ArticleWorld journal of surgical oncology2025
LINC01082 inhibits malignant phenotypes of bladder cancer through sponging miR-1269a.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Pan-Cancer Analysis of microRNA Tissue Specificity and Its Association with Dysregulation.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis work aims to delineate the involvement of LINC01082 in bladder cancer (BC) pathogenesis.
methodsSignificant downregulation of LINC01082 in BC tissues was identified through GEO database analysis (GSE89006). Subsequent validation in GEPIA, TCGA, and clinical cohorts supported these findings. The diagnostic utility was evaluated via ROC curve analysis. Interaction between LINC01082 and miR-1269a, predicted by lncRNASNP, was confirmed by dual luciferase reporter assays. RT-qPCR measured the expression of LINC01082, miR-1269a, and EMT-related genes, while Transwell assays characterized cell migration and invasion.
resultsLINC01082 was found to be significantly underexpressed in BC tissues and cell lines, with excellent diagnostic efficacy. LINC01082 can specifically bind to miR-1269a. When LINC01082 expression is silenced, BC cells exhibit increased migration and invasion capacities, accompanied by a decline in the epithelial marker E-cadherin and an upregulation of mesenchymal markers, including N-cadherin and vimentin. However, these effects can be effectively reversed by adding the miR-1269a inhibitor.
conclusionLINC01082 can downregulate the expression of miR-1269a, thereby inhibiting the migration, invasion, and EMT of BC cells, ultimately hindering the malignant progression of tumors. This study provides new insights into its anticancer effects and molecular mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.